Answer
Durvalumab, a monoclonal antibody, selectively blocks PD‑L1 interactions with PD‑1 and CD80 (B7.1), increasing T-cell activation and antitumour immune responses without inducing antibody-dependent cell-mediated cytotoxicity.
Sources for this answer
- IMFINZI 50 mg/mL concentrate for solution for infusionAstraZeneca UK Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 38Document updated
Sources checked